[Treatment of androgenic alopecia with topical minoxidil].
Minoxidil, a vasodilator, was first marketed in 1979 as an oral antihypertensive. Since hypertrichosis occurred as an adverse effect in most patients treated, a 2% topical solution was developed for use in men with androgenic alopecia. It was approved by the American Food and Drug Administration and by the Israel Ministry of Health. A follow-up of 30 cases treated with the preparation is presented. Efficacy of treatment was assessed by hair counts in a marked area on the balding scalp, as well as by subjective evaluations of patients and physicians. The treatment was beneficial in 63%: balding was slowed in most, while in a minority hair density actually increased. However, in only 6.6% was dramatic cosmetic improvement achieved.
Brenner
S
S
Dermatology Dept., Sourasky Medical Center, Tel Aviv.
Tamir
A
A
D000287:Administration, Topical; D000328:Adult; D000505:Alopecia / Q000188:drug therapy* / Q000517:prevention & control; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008914:Minoxidil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D008914:Minoxidil